Interleukin Raises $3M in Private Placement | GenomeWeb

NEW YORK (GenomeWeb News) – Interleukin Genetics today said it has completed a private placement with Delta Dental Plan of Michigan, resulting in an investment of $3 million.

The investment consists of 500,000 shares of Interleukin Series B convertible preferred stock. Each share is convertible into about 21.86 shares of common stock reflecting a conversion price of $.2745 per share. Delta also obtains one seat on Interleukin's board immediately, replacing one of the Series A directors.

BTIG acted as the exclusive placement agent on the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.